#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14348	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2133	668.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1467	1467	C	837	C,T	769,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14348	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2133	668.6	0	HET	.	.	.	C207T	.	207	207	C	490	490	C	799	C,T	583,151	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26642	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3652	727.1	0	.	n	.	0	T695C	SNP	695	695	T	1011	1011	C	868	C	814	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26642	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3652	727.1	0	.	n	.	0	C1811T	SNP	1811	1811	C	2127	2127	T	852	T,C	615,193	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26642	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3652	727.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2287	2287	C	813	C	761	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26642	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3652	727.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2361	2361	A	851	A	816	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26642	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3652	727.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2913	2913	C	852	C,A,T	795,2,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2138	folP	855	855	100.0	folP.l15.c17.ctg.1	1508	140.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1008	1010	AGC	211;213;211	A;G;C	202;200;200	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	160.3	1	SNP	p	S91F	1	.	.	271	273	TTC	648	650	TTC	171;170;173	T;T;C	163;164;164	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	160.3	1	SNP	p	G95N	0	.	.	283	285	GGC	660	662	GGC	172;170;170	G;G;C,A	165;162;162,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3475	160.3	1	SNP	p	D95G	1	.	.	283	285	GGC	660	662	GGC	172;170;170	G;G;C,A	165;162;162,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1724	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1340	128.0	1	SNP	p	G45D	0	.	.	133	135	GGC	415	417	GGC	237;232;232	G;G;C	222;219;219	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	924	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	977	94.1	0	.	n	.	0	A197.	DEL	197	197	A	519	519	A	208	A	200	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5054	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	173.1	1	SNP	p	D86N	0	.	.	256	258	GAC	512	514	GAC	211;212;214	G;A;C	190;191;194	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5054	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	173.1	1	SNP	p	R87I	0	.	.	259	261	CGT	515	517	CGT	215;217;220	C,A;G;T	193,1;194;201	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5054	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	173.1	1	SNP	p	S87R	1	.	.	259	261	CGT	515	517	CGT	215;217;220	C,A;G;T	193,1;194;201	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5054	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	173.1	1	SNP	p	R87W	0	.	.	259	261	CGT	515	517	CGT	215;217;220	C,A;G;T	193,1;194;201	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5054	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	173.1	1	SNP	p	S88P	0	.	.	262	264	TCC	518	520	TCC	217;215;212	T;C;C	202;201;200	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4148	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2582	159.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1464	1466	GGC	207;205;205	G;G;C	197;195;192	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	A311V	0	.	.	931	933	GCC	1236	1238	GCC	223;225;225	G;C;C	209;213;215	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	I312M	1	.	.	934	936	ATG	1239	1241	ATG	225;225;226	A;T;G,C	216;214;213,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	T316P	0	.	.	946	948	ACC	1251	1253	ACC	238;235;235	A;C;C	221;219;219	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	V316T	1	.	.	946	948	ACC	1251	1253	ACC	238;235;235	A;C;C	221;219;219	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1752	1754	ACC	201;200;199	A;C;C	184;184;187	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1806	1808	GCG	210;210;214	G;C;G	199;201;203	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1806	1808	GCG	210;210;214	G;C;G	199;201;203	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1929	1931	GGT	168;165;165	G;G;T	161;158;159	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1938	1940	AGC	160;161;160	A;G;C	153;150;151	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4072	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2338	173.1	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1956	1958	CCG	137;137;138	C,G;C;G	108,7;111;109	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5442	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3110	174.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1603	1605	CCG	213;210;205	C,T;C;G	179,1;188;177	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2276	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1829	124.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	571	571	C	148	C	138	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2696	porB1b	1038	1038	99.9	porB1b.l6.c17.ctg.1	1668	160.9	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	416	418	CAG	206;204;203	C;A;G	192;191;190	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2696	porB1b	1038	1038	99.9	porB1b.l6.c17.ctg.1	1668	160.9	1	SNP	p	G120K	1	.	.	358	360	AAG	656	658	AAG	216;215;217	A;A;G	207;207;206	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2696	porB1b	1038	1038	99.9	porB1b.l6.c17.ctg.1	1668	160.9	1	SNP	p	A121N	1	.	.	361	363	AAC	659	661	AAC	215;220;222	A;A;C	205;213;213	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2696	porB1b	1038	1038	99.9	porB1b.l6.c17.ctg.1	1668	160.9	1	SNP	p	N121D	0	.	.	361	363	AAC	659	661	AAC	215;220;222	A;A;C	205;213;213	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10498	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4981	210.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1150	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1077	105.4	1	SNP	p	V57M	1	.	.	169	171	ATG	463	465	ATG	236;233;232	A,G;T;G	221,1;220;217	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
